Edition:
United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.66USD
11 Dec 2017
Change (% chg)

$0.26 (+4.81%)
Prev Close
$5.40
Open
$5.36
Day's High
$5.71
Day's Low
$5.22
Volume
7,796
Avg. Vol
5,471
52-wk High
$10.90
52-wk Low
$4.42

Select another date:

Mon, Dec 4 2017

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage:

BRIEF-Therapix Biosciences Q3 loss per share $0.30

* Therapix Biosciences reports third quarter 2017 financial results and provides business update

BRIEF-Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer

* Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Therapix initiates non-clinical studies for its antibacterial program

* Therapix- Initiated non-clinical studies to evaluate efficacy of compound THX-150 with Weizmann Institute of Science & Tel Aviv Sourasky Medical Center​

BRIEF-Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea

* Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01

* THERAPIX SIGNS FORMULATION DEVELOPMENT AND CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01

BRIEF-Therapix's therapy shows reversal of age-related cognitive impairment in pre-clinical study

* Therapix's first-in-class therapy demonstrates reversal of age-related cognitive impairment in pre-clinical study Source text for Eikon: Further company coverage:

BRIEF-Therapix Biosciences posts Q2 loss per share $0.54

* Therapix Biosciences reports second quarter 2017 financial results and provides business update

Select another date: